Synergy Pharmaceuticals Inc (SGYP) Expected to Announce Earnings of -$0.16 Per Share

Analysts expect Synergy Pharmaceuticals Inc (NASDAQ:SGYP) to post earnings of ($0.16) per share for the current fiscal quarter, Zacks reports. Two analysts have issued estimates for Synergy Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.17). Synergy Pharmaceuticals posted earnings of ($0.33) per share during the same quarter last year, which suggests a positive year-over-year growth rate of 51.5%. The business is expected to report its next quarterly earnings report on Wednesday, August 8th.

According to Zacks, analysts expect that Synergy Pharmaceuticals will report full year earnings of ($0.59) per share for the current fiscal year, with EPS estimates ranging from ($0.62) to ($0.55). For the next financial year, analysts forecast that the company will report earnings of ($0.29) per share, with EPS estimates ranging from ($0.34) to ($0.23). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Synergy Pharmaceuticals.

Synergy Pharmaceuticals (NASDAQ:SGYP) last issued its earnings results on Thursday, May 10th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.01. Synergy Pharmaceuticals had a negative net margin of 773.82% and a negative return on equity of 652.66%. The business had revenue of $8.59 million for the quarter, compared to analyst estimates of $11.18 million. During the same period in the previous year, the business earned ($0.30) EPS. The firm’s revenue was up 776.5% on a year-over-year basis.

A number of research firms have commented on SGYP. HC Wainwright set a $7.00 price target on shares of Synergy Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, March 5th. Zacks Investment Research upgraded shares of Synergy Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 21st. BidaskClub upgraded shares of Synergy Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 21st. Oppenheimer restated a “hold” rating on shares of Synergy Pharmaceuticals in a research report on Thursday, March 22nd. Finally, Cantor Fitzgerald restated a “hold” rating on shares of Synergy Pharmaceuticals in a research report on Sunday. One analyst has rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $8.08.

A number of large investors have recently added to or reduced their stakes in the business. BlackRock Inc. lifted its position in shares of Synergy Pharmaceuticals by 8.7% during the fourth quarter. BlackRock Inc. now owns 21,998,125 shares of the biopharmaceutical company’s stock worth $49,056,000 after purchasing an additional 1,761,725 shares in the last quarter. Hikari Power Ltd lifted its position in shares of Synergy Pharmaceuticals by 5.3% during the first quarter. Hikari Power Ltd now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $3,660,000 after purchasing an additional 100,000 shares in the last quarter. CVI Holdings LLC acquired a new position in shares of Synergy Pharmaceuticals during the first quarter worth approximately $3,235,000. Schwab Charles Investment Management Inc. lifted its position in shares of Synergy Pharmaceuticals by 16.4% during the first quarter. Schwab Charles Investment Management Inc. now owns 1,223,644 shares of the biopharmaceutical company’s stock worth $2,240,000 after purchasing an additional 172,236 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Synergy Pharmaceuticals by 2,579.3% during the first quarter. Millennium Management LLC now owns 504,383 shares of the biopharmaceutical company’s stock worth $923,000 after purchasing an additional 485,558 shares in the last quarter. Hedge funds and other institutional investors own 44.26% of the company’s stock.

Synergy Pharmaceuticals opened at $1.77 on Friday, MarketBeat reports. The stock has a market capitalization of $444.13 million, a price-to-earnings ratio of -1.74 and a beta of 1.23. Synergy Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $4.64. The company has a current ratio of 3.09, a quick ratio of 2.71 and a debt-to-equity ratio of -3.01.

About Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat gastrointestinal diseases and disorders. Its lead product is plecanatide, a novel uroguanylin based gastrointestinal platform that is traded under the TRULANCE name for the treatment of chronic idiopathic constipation and irritable bowel syndrome.

Get a free copy of the Zacks research report on Synergy Pharmaceuticals (SGYP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)

Receive News & Ratings for Synergy Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply